GlassScriptPhysician profile
Nikhil Barot
NPI 1518155928
$2,070.73
in general payments reported to CMS, 2019-2025
25 companies · $613 in 2025
The $613 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $34.21 · 2023: $304 · 2024: $702 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,618.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $269.26 | 2019-2025 | Tyvaso, Tyvaso |
| Actelion Pharmaceuticals US, INC. | $225.03 | 2019-2025 | Uptravi, Opsumit |
| Insmed, INC. | $198.67 | 2024-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.00 | 2023-2025 | Ofev |
| Amgen INC. | $166.34 | 2023-2024 | Tezspire |
| Philips North America LLC | $149.05 | 2023-2025 | (8874) Incourage, Vest Therapy Und |
| Merck Sharp & Dohme LLC | $119.81 | 2023-2025 | Winrevair |
| Janssen Pharmaceuticals, INC | $114.53 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $83.19 | 2019 | |
| Medtronic, INC. | $78.78 | 2024-2025 | Illumisite, Puritan Bennett |
| Baxter Healthcare | $65.40 | 2023-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Metaneb System |
| Mylan Specialty L.P. | $48.92 | 2024 | Yupelri |
| Viatris Specialty LLC | $43.53 | 2025 | Yupelri |
| Atos Medical INC | $35.79 | 2024 | Provox Life Home Hme |
| Astellas Pharma US INC | $33.47 | 2023 | Cresemba |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $30.39 | 2023 | Evis Exera III Bronchovideoscope |
| La Jolla Pharmaceutical Company | $29.79 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $29.76 | 2024 | Andexxa |
| Glaxosmithkline, LLC. | $26.94 | 2025 | Nucala |
| Edwards Lifesciences Corporation | $26.40 | 2024 | Hemosphere |
| Mallinckrodt Enterprises LLC | $24.19 | 2019 | |
| Genentech USA, INC. | $22.80 | 2019 | |
| Verona Pharma, INC. | $21.59 | 2025 | Ohtuvayre |
| Electromed, INC. | $21.42 | 2024 | Smartvest |
| Gilead Sciences, INC. | $20.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikhil Barot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.